Keep in touch with meI'm using Intch to connect with new people. Use this link to open chat with me via Intch app
Work Background
EmicAiAdvisory Board Member
May. 2024
AstraZenecaAssociate Director, Global Oncology Commercial Strategy (GI Cancers)
Aug. 2023Washington DC-Baltimore AreaLead market research, forecasting, and advanced analytics for U.S., EU5, China, & Japan in early hepatocellular carcinoma (HCC), resectable/early and advanced biliary tract cancers (BTCs), locally advanced / unresectable esophageal squamous cell carcinoma (ESCC), and resectable gastric and gastroesophageal junction cancer (GC/GEJC) Executed global launch in early HCC, collaborating closely with Global Commercial colleagues to understand the disease area, market opportunity, HCP archetypes in a complex indication (e.g., High Risk of Recurrence eHCC is not defined in guidelines) Responsible for insights and market assessment for cross-functional deliverables across multiple assets (e.g., I-O, ADCs, bi-specifics), including Tumor Strategy Plans for BTC, HCC, & Gastric Cancers Responsible for insights and market assessment for brand deliverables in aBTCs, eHCC, GEJC/GC, and locally advanced ESCC
AstraZenecaForecasting Leader (Immuno-Oncology), US - Oncology Business Unit Strategy
Jan. 2023 - Aug. 2023Gaithersburg, Maryland, United StatesLed forecasting for Immuno-Oncology (I-O) products in Neoadjuvant & Adjuvant Stage II-IIIb Non-Small Cell Lung Cancer (NSCLC), Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), Stage IV Metastatic Non-Small Cell Lung Cancer (mNSCLC), and Extensive Stage Small Cell Lung Cancer (ES-SCLC) for U.S. market Partnered with Brand Strategy / Marketing teams to develop and execute commercial strategy across all forecasted indications (e.g., NSCLC, SCLC), including market segmentation, key performance indicator selection and targeting, AdBoards, market research (e.g., demand studies, patient journeys, drivers & barriers, etc.), and conference coverage (e.g., ASCO, AACR, ESMO) Conducted primary market research and forecasting buildout ahead of I-O product launch in Stage IV Metastatic Non-Small Cell Lung Cancer (NSCLC) and Neoadjuvant & Adjuvant Stage II-IIIb Non-Small Cell Lung Cancer (NSCLC) for U.S. market Conducted competitive intelligence across all I-O in-line and late-stage clinical pipeline indications (10+ indications) as well as build out comprehensive competitive intelligence database and presentation material for C-Suite Executives
AstraZenecaForecasting & Performance Analytics, US - Oncology Business Unit Strategy
Aug. 2021 - Jan. 2023Gaithersburg, Maryland, United StatesLed forecasting for Immuno-Oncology product in Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Stage IV Metastatic Non-Small Cell Lung Cancer (mNSCLC) for U.S. market Managed performance analytics for Immuno-Oncology product ($1B+ revenue) across all in-line lung cancer indications, including Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), & Stage IV Metastatic Non-Small Cell Lung Cancer (NSCLC) for U.S. market
L.E.K. ConsultingAssociate Consultant, Life Sciences Practice
Jul. 2020 - Aug. 2021Greater Boston AreaEstablished new business model for clinical stage biotechnology company, modelling risk-adjusted NPV for seven preclinical to clinical stage assets across therapeutic areas (e.g., Autoimmune / Immunology, Oncology, Cardio-metabolic, and Neurology) to assess current portfolio and develop future strategy, including franchise development, spinouts, and divestitures. Developed a global commercial and operational strategy for a U.S. biotech client for an Infectious Disease treatment (i.e., COVID-19), specifically focused on ex-U.S. market entry strategies, international pricing and reimbursement, and competitive pipeline analysis Modeled market opportunity assessment in high beta, advanced modality therapy ingredient (e.g., pDNA) and conducted M&A screen for strategic buyer entrance into upstream therapeutic ingredient space Modeled industry outlook for vendor due diligences (VDDs) in the following industries: pharmaceutical manufacturing equipment (e.g., fill-finish, lyophilization) and consumer health formulation contract development and manufacturing organization (CDMO) services Co-author on "COVID-19 Funding Snapshot for Pharma Developers/Manufacturers"
Intch is a Professional Networking App for the Future of WorkSee more people like Tony on Intch
300k+ people
130+ countries
AI matching
Get Intch if you'd like to
500665 people
18
Technologist, Project/Program Manager
21
Education Consultant
15
Human Resources @ UB Greensfelder
125876 people
15
Principal Consultant @ Marketing Endeavors Strategic Consulting
42
Senior Mining Engineer @ Riot blockchain
62
CEO /Co-founder @ The James Ruff Group/ HardMoney Loans